Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04072432 · ClinicalTrials.gov registry record · Phase 1

A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease

A Phase 1 study of Healthy Volunteers and Chronic Kidney Disease, sponsored by Renibus Therapeutics.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT04072432 is a Phase 1 study of Healthy Volunteers and Chronic Kidney Disease that has completed, run by Renibus Therapeutics. The registered enrollment target is 18 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04072432, a Phase 1 study of Healthy Volunteers and Chronic Kidney Disease, has completed, sponsored by Renibus Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 1b, single center, dose-escalating study evaluating the safety, tolerability, and pharmacodynamic effect of RBT-3 in healthy volunteers and in subjects with stage 3-4 chronic kidney disease.

Interventions

  • DRUG RBT-3

Study Locations (1)

Florida

  • Riverside Clinical Research - Edgewater

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2018-10-21
Est. Completion 2019-08-26
Phase Phase 1

Sponsor

Renibus Therapeutics

9 total trials

What the Registry Record Tells You About NCT04072432

The ClinicalTrials.gov registry entry for NCT04072432 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (96% lower). The listed sponsor is Renibus Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which RBT-3 is the first listed.

NCT04072432 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT04072432 about?

NCT04072432 is a clinical study titled "A Study of RBT-3 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease". This is a Phase 1b, single center, dose-escalating study evaluating the safety, tolerability, and pharmacodynamic effect of RBT-3 in healthy volunteers and in subjects with stage 3-4 chronic kidney disease.

What is the current status of trial NCT04072432?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-10-21. Estimated completion is 2019-08-26.

What conditions does trial NCT04072432 study?

This clinical trial studies the following conditions: Healthy Volunteers, Chronic Kidney Disease.

What interventions are being tested in trial NCT04072432?

The interventions under investigation include: RBT-3 (DRUG).

Who is sponsoring clinical trial NCT04072432?

This trial is sponsored by Renibus Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04072432 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.